Compare stocks
Add stockDates End of financial period
| #1 | #2 | #3 | #4 | #5 | #6 | #7 | #8 | |
|---|---|---|---|---|---|---|---|---|
| Remove Pfizer Inc | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 |
| Remove Analog Devices Inc | Aug 26 | May 26 | Jan 26 | Nov 25 | Aug 25 | May 25 | Feb 25 | Nov 24 |
| Remove T-Mobile US, Inc. | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 |
| Remove Exelon Corp | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 |
Profit ROIC / ROE/ROA / ROE / ROA
| #1 | #2 | #3 | #4 | |
|---|---|---|---|---|
| Pfizer Inc (ROE/ROA) | 36.4% | 40.7% | 42.5% | 42.1% |
| Analog Devices Inc (ROIC) | 8.9% | 7.5% | 6.3% | 5.6% |
| T-Mobile US, Inc. (ROE/ROA) | 60.2% | 60.8% | 61.3% | 61.8% |
| Exelon Corp (ROIC) | 5.7% | 5.7% | 5.8% | 5.7% |
Growth Sales and OCF growth / Sales and net income growth
| #1 | #2 | #3 | #4 | |
|---|---|---|---|---|
| Pfizer Inc | -5.1% | -5.4% | -4.4% | 17.7% |
| Analog Devices Inc | 31.6% | 29.1% | 26.5% | 19.0% |
| T-Mobile US, Inc. | 10.7% | 12.2% | 14.1% | 13.0% |
| Exelon Corp | 9.1% | 7.8% | 9.5% | 5.7% |
Payout Shareholder distributions / net income
| #1 | #2 | #3 | #4 | #5 | |
|---|---|---|---|---|---|
| Pfizer Inc | 150% | 127% | 123% | 121% | 152% |
| Analog Devices Inc | 135% | 149% | 163% | 172% | 174% |
| T-Mobile US, Inc. | 141% | 142% | 128% | 127% | 120% |
| Exelon Corp | 58% | 60% | 58% | 60% | 59% |
Safety Equity/assets and OCF stability / Equity/assets and net income stability
| Balance | Stability | |
|---|---|---|
| Pfizer Inc | 42.6% | 62.2% |
| Analog Devices Inc | 69.8% | 86.9% |
| T-Mobile US, Inc. | 27.1% | 93.8% |
| Exelon Corp | 25.0% | 89.6% |
Price Earnings and FCF yield / Earnings and book yield
| Earnings | FCF / Book | |
|---|---|---|
| Pfizer Inc | $2.75 | $6.97 |
| Analog Devices Inc | $2.35 | $2.81 |
| T-Mobile US, Inc. | $5.91 | $10.30 |
| Exelon Corp | $6.31 | $-4.91 |
